Drug for Mesothelioma Fails Trial

Quoted from http://www.medpagetoday.com/MeetingCoverage/ECCO-ESMO/28768

Drug for Mesothelioma Fails Trial

ByKristina Fiore, Staff Writer, MedPage Today
Published: September 28, 2011
ReviewedbyRobert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
STOCKHOLM — Vorinostat (Zolinza) failed to extend survival as a second-line therapy in patients with malignant pleural mesothelioma, researchers said here.

The phase III trial, the largest of its kind in advanced mesothelioma, failed to meet its primary endpoint of lengthening overall survival in those who failed prior chemotherapy, according to Lee Krug, MD, of Memorial Sloan-Kettering Cancer Center in New York.

Krug reported the findings at a presidential session at the European Multidisciplinary Cancer Congress, formerly known as the Congress of the European Cancer Organization and European Society for Medical Oncology.

“Unfortunately, there was no benefit with regard to overall survival compared with placebo,” Krug said. “There was a statistically significant improvement in progression-free survival, but it wasn’t clinically significant.”

Krug said the average survival in advanced mesothelioma is about a year from diagnosis, with 2,000 to 3,000 cases reported annually in the U.S. He noted that cases are usually related to asbestos exposure decades earlier, and are expected to peak between 2015 and 2020 since the product has fallen out of use.

Currently, there is no standard second-line chemotherapy for patients with the disease. Earlier studies have shown that a small number of mesothelioma patients treated with the drug had stable disease that lasted four to 13 months. So the researchers launched a phase III trial to investigate its overall survival and tolerability

[Article continues at original source]

Speak Your Mind


Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
Tel: (800) 426-9535
Disclaimer and Copyright